Bundibugyo virus, a rare Ebola species, has infected approximately 750 people across the Democratic Republic of Congo and Uganda, killing over 170, according to the World Health Organization. The outbreak marks only the third documented occurrence of this strain, first identified in 2007, raising concerns among global health officials who expect case numbers to rise.

The virus spreads through direct contact with infected bodily fluids, including blood, vomit, and saliva, primarily in healthcare settings. Unlike airborne transmission, the virus requires entry through mucus membranes or skin tears. Early symptoms mirror severe flu or malaria—high fever, headache, muscle pain—making rapid diagnosis challenging for medical professionals in affected regions.

Healthcare systems face significant strain as treatment options remain limited to supportive care. No approved vaccine exists for Bundibugyo specifically, though candidates are expected to emerge soon. The outbreak's economic impact includes increased healthcare costs and reduced productivity in affected communities, while pharmaceutical companies may accelerate vaccine development investments.

Historically, Bundibugyo has shown a 30-50% mortality rate, lower than other Ebola species. However, insufficient outbreak data makes definitive projections difficult. Survivors often experience long-term complications including vision loss and neurological issues, creating sustained healthcare burdens for regional medical infrastructure.